Teriflunomide

Drug Profile

Teriflunomide

Alternative Names: A-77-1726; Aubagio; AVE-1726; HMR-1726; HMR1726D; RS-61980; SU-0020

Latest Information Update: 12 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sanofi-aventis
  • Developer Genzyme Corporation; Sanofi; Sanofi Genzyme
  • Class Antirheumatics; Hydroxybutyrates; Nitriles; Small molecules; Toluidines
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis

Most Recent Events

  • 25 Apr 2017 Efficacy and adverse events data from an extension of the phase III TOPIC trial in Multiple sclerosis released by Sanofi Genzyme
  • 22 Apr 2017 Efficacy and adverse events data from an extension of the phase III TOPIC trial in Multiple sclerosis presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 22 Apr 2017 Efficacy data from a pooled analysis of the extensions of phase III TEMSO and TOWER trials in Multiple sclerosis presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top